BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29133622)

  • 21. Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
    Pigné T; Lévy M; Ducharme O; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Prey S
    Melanoma Res; 2023 Jun; 33(3):252-256. PubMed ID: 36919691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 23. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
    PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
    Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
    Lee Y; Park D
    Anticancer Res; 2021 Mar; 41(3):1387-1399. PubMed ID: 33788730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of activated c-Met with NRAS-mutated human melanomas.
    Chattopadhyay C; Ellerhorst JA; Ekmekcioglu S; Greene VR; Davies MA; Grimm EA
    Int J Cancer; 2012 Jul; 131(2):E56-65. PubMed ID: 22020736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.
    Frankel AE; Eskiocak U; Gill JG; Yuan S; Ramesh V; Froehlich TW; Ahn C; Morrison SJ
    Neoplasia; 2017 Apr; 19(4):255-260. PubMed ID: 28278423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
    Maio M; Carlino MS; Joshua AM; McWhirter E; Ribas A; Ascierto PA; Miller WH; Butler MO; Ferrucci PF; Zielinski RR; Del Vecchio M; Gasal E; Ghori R; Diede SJ; Croydon E; Hamid O
    Eur J Cancer; 2022 Jan; 160():1-11. PubMed ID: 34801354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.
    Schick U; Kyula J; Barker H; Patel R; Zaidi S; Gregory C; Hafsi H; Roulstone V; Deutsch E; McLaughlin M; Harrington K
    Radiother Oncol; 2015 Nov; 117(2):364-75. PubMed ID: 26163092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trametinib-Resistant Melanoma Cells Displaying MITF
    Koziej P; Kluszczynska K; Hartman ML; Czyz M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.
    Phadke M; Remsing Rix LL; Smalley I; Bryant AT; Luo Y; Lawrence HR; Schaible BJ; Chen YA; Rix U; Smalley KSM
    Mol Oncol; 2018 Jan; 12(1):74-88. PubMed ID: 29112787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
    Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.
    Bowyer SE; Rao AD; Lyle M; Sandhu S; Long GV; McArthur GA; Raleigh JM; Hicks RJ; Millward M
    Melanoma Res; 2014 Oct; 24(5):504-8. PubMed ID: 24933606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.